Skip to main content

DESARROLLO DE NUEVAS INTERVENCIONES TERAPEUTICAS PARA LA ENFERMEDAD DE PARKINSON BASADAS EN MODULADORES DE LA INTERACCION DEL SENSOR DE CALCIO NCS-1

PID2022-137331OB-C32

•
Funding agency name Agencia Estatal de Investigación
Funding agency acronym AEI
Program Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprogram Subprograma Estatal de Generación de Conocimiento
Call Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Call year 2022
State Plan 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre FUNDACION PARA LA INVESTIGACION BIOMEDICA DEL HOSPITAL UNIVERSITARIO RAMON Y CAJAL

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

FDA Drug Repurposing Uncovers Modulators of Dopamine D2 Receptor Localization via Disruption of the NCS-1 Interaction

  • Muñoz-Reyes, Daniel
  • Aguado, Lorena
  • Arroyo-Urea, Sandra
  • Requena, Carlos
  • Pérez-Suárez, Sara
  • Sánchez-Yepes, Sonia
  • Argerich, Josep
  • Miró-Rodríguez, Celia
  • Ulzurrun, Eugenia
  • Rodríguez-Martín, Eulalia
  • García-Nafría, Javier
  • Campillo, Nuria E.
  • Mansilla, Alicia
  • Sánchez-Barrena, María José
Dopamine D2 receptor (D2 R) regulates key aspects of motor control, cognition, and reward. Its function depends not only on ligand binding and signaling efficacy but also on the dynamic control of receptor localization at the cell surface. Neuronal calcium sensor 1 (NCS-1) interacts with D2 R in a Ca2+ -dependent manner. Using in vitro and cellular assays, we found that NCS-1 promotes D2 R trafficking to the plasma membrane through active exocytosis while preserving canonical receptor pharmacology. A screen of FDA-approved drugs identified protein–protein interaction (PPI) modulators targeting the NCS-1/D2 R interface. Azilsartan medoxomil, atorvastatin, and vilazodone disrupt this interaction, reducing D2 R surface expression. Structural studies revealed that these compounds target NCS-1, overlap the D2 R binding site, and perturb the dynamics of the regulatory helix H10. These findings reveal an unexploited intracellular mechanism to modulate D2 R function via PPI modulation, offering a novel strategy to fine-tune dopaminergic tone beyond receptor blockade or direct agonism., This work was supported by grants PID2019-111737RB-I00 and PID2022-137331OB-C31 (to M.J.S.B.); PID2020 113359GA-I00 and PID2023-148739NB-I00 (to J.G.N.);PID2022-137331OB-C32 (to A.M.); PID2022-137331OB-C33 (to N.E.C.); and the Spanish “Ramón y Cajal” program (to J.G.N. and A.M.), which were funded by the MICIU/AEI/ 10.13039/501100011033, FEDER and EU. S.P.S. was supported by a contract from the “Programa de Empleo Juvenil de la Comunidad de Madrid” PEJ-2020-AI/BMD 18666 and CMR by a Spanish National Research Council JAE Intro grant (JAEINT_23_00101)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

An AI-based approach accelerates the discovery of protein–protein interaction modulators targeting NCS-1

  • González-García, Eduardo
  • Miró-Rodríguez, Celia
  • Ulzurrun, Eugenia
  • Toledano, Óscar
  • Pérez-Suarez, Sara
  • Aguado, Lorena
  • Sánchez-Barrena, M José
  • Mansilla, Alicia
  • Naveiro, Roi
  • Campillo, Nuria E.
Drug repurposing is an efficient strategy to accelerate the identification of therapeutic compounds by finding new uses for existing drugs. Here, we leveraged artificial intelligence (AI) to optimize this process and discover protein–protein interaction (PPI) modulators targeting the Neuronal Calcium Sensor 1. AI models were trained on large datasets of known PPIs, protein structures, and small molecular graphs to predict binding score. Using virtual screening of an FDA-approved drug library, the models generated a prioritized list of candidates. The most promising compounds were selected for experimental validation. This integrated approach efficiently reduced experimental workload, time, and cost, leading to the identification of dipyridamole as a selective modulator of the interaction between NCS-1 and the dopamine D2 receptor. The crystal structure of NCS-1 in complex with dipyridamole elucidates its mechanism of modulation. Our findings highlight the potential of AI to streamline and accelerate the discovery of novel therapeutic PPI modulators, The work was supported by grants PID2022-137331OB-C31 (to MJSB), PID2022-137331OB-C32 (to AM) and PID2022-137331OB-C33 (to NEC), which were funded by MICIU/AEI/10.13039/501100011033, FEDER and EU. SPS was contracted through project PDC2022-133775 I00/AEI/10.13039/501100011033, co-funded by the European Union Next Generation EU., Peer reviewed, Modelo experimental alternativo-NAM, in silico, in vitro - Tipos celulares - líneas inmortalizadas humanas
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

FDA Drug Repurposing Uncovers Modulators of Dopamine D<sub>2</sub> Receptor Localization via Disruption of the NCS-1 Interaction

  • Muñoz-Reyes, Daniel
  • Aguado, Lorena
  • Arroyo-Urea, Sandra
  • Requena, Carlos
  • Pérez-Suárez, Sara
  • Sánchez-Yepes, Sonia
  • Argerich, Josep
  • Miró-Rodríguez, Celia
  • Ulzurrun, Eugenia
  • Rodríguez-Martín, Eulalia
  • García-Nafría, Javier
  • Campillo, Nuria E.
  • Mansilla, Alicia
  • Sánchez-Barrena, María José
Dopamine D2 receptor (D2R) regulates key aspects of motor control, cognition, and reward. Its function depends not only on ligand binding and signaling efficacy but also on the dynamic control of receptor localization at the cell surface. Neuronal calcium sensor 1 (NCS-1) interacts with D2R in a Ca2+-dependent manner. Using in vitro and cellular assays, we found that NCS-1 promotes D2R trafficking to the plasma membrane through active exocytosis while preserving canonical receptor pharmacology. A screen of FDA-approved drugs identified protein–protein interaction (PPI) modulators targeting the NCS-1/D2R interface. Azilsartan medoxomil, atorvastatin, and vilazodone disrupt this interaction, reducing D2R surface expression. Structural studies revealed that these compounds target NCS-1, overlap the D2R binding site, and perturb the dynamics of the regulatory helix H10. These findings reveal an unexploited intracellular mechanism to modulate D2R function via PPI modulation, offering a novel strategy to fine-tune dopaminergic tone beyond receptor blockade or direct agonism.